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| INTRODUC TI ON
Portal hypertension, as assessed by hepatic venous pressure gradient (HVPG), drives the development of complications (ie, hepatic decompensation) in patients with advanced chronic liver disease (ACLD). [1] [2] [3] [4] Animal studies have shown that diet-induced steatohepatitis is associated with the development of portal hypertension in the absence of fibrosis 5 by inducing sinusoidal endothelial dysfunction and thereby increasing intrahepatic vascular resistance. 6 These results
were confirmed in a small series of patients with noncirrhotic nonalcoholic fatty liver disease (NAFLD) reporting an association between steatosis and elevated portal pressure. 7 Transient elastography (TE) has been shown to correlate with HVPG [8] [9] [10] [11] and the development of complications of portal hypertension. 12, 13 TE-based controlled attenuation parameter (CAP) measurement is a novel tool for the quantification of hepatic steatosis, 14 and robust cut-offs for different grades of hepatic steatosis have previously been established by individual patient-based meta-analysis. 15 Recently, CAP has been linked to the incidence of liver-related events (LRE) in patients with compensated ACLD (cACLD). 16 Importantly, this study did not provide information on HVPG, which is a well-established predictor of hepatic decompensation. 13, 17 Thus, it is unclear, whether CAP is an independent predictor of LRE.
Another recent study did not observe an association between CAP and hepatic decompensation in patients with liver disease. 13 However, the majority of patients included in the latter study did not have significant liver fibrosis, as reflected by low median liver stiffness values. Accordingly, only a very small proportion of patients developed hepatic decompensation, which substantially limits the generalizability of the findings to patients with ACLD, 13 who are at considerable risk of LRE. 18 In addition, the role of CAP in predicting further hepatic decompensation in patients with decompensated cirrhosis (DC) remains unknown.
Therefore, we aimed to assess the prognostic value of CAP for first (cACLD) and further (DC) hepatic decompensation in a thoroughly characterized cohort of ACLD patients undergoing TE with CAP including a large subgroup of patients who also underwent simultaneous HVPG measurement. 
| PATIENTS AND ME THODS

| Study design
| Patients and definitions
Patients were excluded if they had (a) invalid TE measurements (nonfasting, <10 valid measurements, IQR/median >0. Patients were grouped according to the presence (decompensated cirrhosis, DC) or absence (compensated advanced chronic liver disease, cACLD) of previous hepatic decompensation. 26 In patients with DC, the following events were considered as further hepatic 
| Noninvasive measurements and cut-offs for hepatic steatosis
Hepatic steatosis was assessed by TE-based CAP using a FibroScan® 502 Touch (Echosens, Paris, France), applying previously described reliability criteria for TE. 20 The following cut-offs for steatosis grades were derived from a recently published meta-analysis 15 30 However, if we were unable to obtain liver stiffness measurement by TE (eg, due to pronounced perihepatic ascites), patients were excluded. Patients were censored at the time of liver transplantation, end of follow-up or non-liver-related death. Cox regression included variables that showed differences between patients with and without first/further hepatic decompensation or those which we considered highly relevant based on the previous literature (eg, HVPG). Area under the receiver operating characteristic curve (AUROC) analysis was performed for determining the optimal CAP cut-off for predicting hepatic decompensation. A two-sided P-value ≤0.05 was considered as statistically significant. 
| Statistics
| Ethics
| RE SULTS
| Patients
In total, 3601 patients underwent simultaneous TE and CAP measurements within the inclusion period ( Figure 1 ). As depicted in Figure 1 , 2714 patients had to be excluded. Finally, 430 patients were included for further analysis ( Figure 1 ). A total of 292 patients were assigned to the cACLD and 138 to the DC group. Half of patients (n = 86 in the cACLD and n = 103 in the DC group) also underwent simultaneous HVPG measurement.
| Patient characteristics (Tables 1 and 2)
Patient characteristics are shown separately for cACLD (Table 1) and DC patients ( Table 2 ). The majority of cACLD patients were male (65%) Similarly, more than half of DC patients were male (62%) with a mean age of 54 ± 12 years. The majority of patients (n = 68) had alcoholic liver disease, followed by HCV infection (n = 30), cholestatic liver disease (n = 6), NAFLD (n = 4), HBV infection (n = 3) and other aetiologies of liver disease (n = 27). The most common previous decompensating event was ascites (79%), followed by hepatic encephalopathy (33.0%) and variceal bleeding (31%). The mean CAP value was 235 ± 66 dB/m, and 38% had any hepatic steatosis (≥248 dB/m). (15) 40 (15) 3 (12) Other, n (%) 38 (13) 34 (13) 4 (16) Cryptogenic, n (%) 16 (5) 12 (4) 4 (16) Diabetes, n (%) 59 (20) 51 ( 
| Development of first/further hepatic decompensation and ACLF (Figure 2)
During a median follow-up of 22 (13-32) months, 25 of 292 (9%) cACLD patients developed first hepatic decompensation (Figure 2A ).
In the DC group, 46/138 (33%) patients experienced further hepatic decompensation during a median follow-up period of 12.1 (6-24) months ( Figure 2B ). The most common decompensating event in the cACLD group was new onset of ascites, which occurred in 15 (5%) patients, followed by de novo hepatic encephalopathy (n = 5, 2%), and first variceal bleeding (n = 5, 2%). In the DC group, the major event leading to further hepatic decompensation was requirement of paracentesis (n = 19, 14%), followed by hospital admission for hepatic encephalopathy grade 3/4 (n = 13, 9%), and variceal (re-) bleeding (n = 9, 6%), and five additional patients (4%) died from a liver-related cause. 
| Comparison of baseline characteristics between
patients with and without first/further hepatic decompensation during follow-up (Tables 1 and 2) Patients with first hepatic decompensation (cACLD group) during follow-up had significantly lower baseline serum albumin levels (37 ± 5 vs 42 ± 4 g/L; P < 0.001), significantly higher MELD-Na score (12 ± 4 vs 9 ± 3 points; P = 0.001) as well as significantly higher liver stiff- Other, n (%) 17 (12) 11 (12) 6 (13) Cryptogenic, n (%) 16 (12) 10 (11) 6 (13) Diabetes, n (%) 23 (17) 16 (17) 246 ± 59 dB/m; P = 0.126) were comparable between cACLD patients with and without first hepatic decompensation (Table 1) .
MELD-Na score (16 ± 5 vs 14 ± 5 points; P = 0.004), proportion of patients with previous or current hepatic encephalopathy (46% vs 26%; P = 0.021) and baseline HVPG (21 vs 19 mm Hg; P = 0.023; in patients with available data) were significantly higher in patients presenting with further hepatic decompensation (DC group).
Again, CAP values (238 ± 66 vs 231 ± 68 dB/m; P = 0.575) as well as the other evaluated baseline characteristics were comparable between DC patients with and without further hepatic decompensation (Table 2 ).
| Predictors of the development of first/further hepatic decompensation (Table 3)
Multivariate Cox regression analysis evaluating predictors of first (Table 3A) . In contrast, neither CAP nor liver stiffness was associated with first hepatic decompensation.
In patients with DC, multivariate Cox regression analysis showed that higher MELD-Na score (per point; HR: 1.12 [95% CI: 1.05-1.19]; P < 0.001) was the only independent predictor for the development of further hepatic decompensation (Table 3B) . Moreover, history of or current hepatic encephalopathy tended to increase the risk of further hepatic decompensation (HR: 1.68 [95% CI: 0.94-3.01]; P = 0.082). However, neither CAP nor a history of or current ascites was independently predictive of further hepatic decompensation. (Table S1 ). Furthermore and not surprisingly, the proportion of patients with (N)AFLD was significantly higher in the CAP ≥248 dB/m subgroup (cACLD: 20% vs 8%, P = 0.037; Table S2 ).
| Predictors of the development of first/further hepatic decompensation in patients with information on HVPG (
Importantly, in the subgroup of patients who underwent HVPG measurement, HVPG was comparable between patients with and without any hepatic steatosis (CAP <248 dB/m: 18 (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) vs CAP ≥248 dB/m: 16 (11-21); P = 0.296).
We used Kaplan-Meier analysis and log-rank test to compare the incidence of first/further hepatic decompensation. As shown in Figure 2 , there was no difference in the incidence of first/further hepatic decompensation, neither in the cACLD (log-rank test: P = 0.065), nor in the DC group (log-rank test: P = 0.578). When using a CAP cut-off ≥220 dB/m, CAP even had a protective effect for the development of first hepatic decompensation as shown in Figure S2 (log-rank test: P = 0.021). 
| Impact of aetiological and supportive treatment (Table S4A-D)
Furthermore, as aetiological and supportive treatments might have impacted our results, the number of patients receiving vs not receiving anti-HCV and non-selective beta-blocker (NSBB) therapy during follow-up was compared (Table S4A -D). In the cACLD group, 80%
(n = 64) of HCV-infected patients with a CAP <248 dB/m and 88%
(n = 82) of HCV-infected patients with a CAP ≥248 dB/m (P = 0.140) achieved sustained virologic response (SVR) to anti-HCV therapy during the study period. In the DC group, results were comparable, n = 14 (70%) vs n = 6 (60%; P = 0.690) had SVR.
Additionally, NSBB treatment was equally distributed between patients with a CAP <248 dB/m vs patients with a CAP ≥248 dB/m (cACLD group: 40 (34%) vs 53 (31%), P = 0.536; DC group: 55 (65%) vs 35 (66%), P = 0.873).
| D ISCUSS I ON
The development of noninvasive tools for the diagnosis of portal hypertension and prediction of complications is of great clinical relevance. TE has been shown to be a useful method for predicting CSPH 25,31 and liver-related events. 12, 13 Besides liver stiffness, CAP has recently been proposed as an independent predictor of clinical decompensation in patients with cACLD. 16 The results of Margini and co-workers indicate that CAP is particularly useful for subclassifying patients with liver stiffness values suggestive of CSPH (ie, ≥21 kPa). 16 In their study, a CAP value ≥220 dB/m seemed to be an excellent predictor of first hepatic decompensation, 16 which was explained by the potential role of hepatic steatosis for liver disease progression.
In our cohort, we studied the prognostic impact of CAP using a cut-off of ≥248 dB/m. This value was chosen as it has recently been shown to be the optimal cut-off for diagnosing hepatic steatosis in an individual patient data meta-analysis. 15 Interestingly, using this cut-off, CAP had no impact on the incidence of first hepatic decompensation in patients with cACLD, even after adjusting for other important prognostic parameters (eg, MELD-Na, serum albumin levels, as well as HVPG in a subgroup of patients). Furthermore, HVPG values were comparable between patients with and without hepatic steatosis, suggesting that hepatic steatosis does not aggravate portal hypertension.
Since aetiological treatment (eg, HCV therapy 24 ) as well as NSBB use 32 could potentially have influenced our results, the proportions of patients achieving SVR or receiving NSBB treatment were compared. Importantly, these treatments were equally distributed between patients with CAP </≥248 dB/m, and thus, it is unlikely that they had an impact on our results. TA B L E 3 Predictors of the development of (further) hepatic decompensation in (A) patients with compensated advanced chronic liver disease and (B) decompensated cirrhosis fibrosis progression, and thus, patients with hepatic steatosis had less severe liver disease at baseline, as indicated by higher serum albumin levels and lower MELD-Na. [33] [34] [35] Importantly, after adjusting for these and other potentially relevant baseline characteristics, we observed no independent association between CAP and first hepatic decompensation.
In contrast to the study by Margini et al, 16 our study comprised a subgroup of patients with information on HVPG, which is, based on the literature, a highly relevant predictor of hepatic decompensation 17 and liver-related mortality. 26, 36 Although the authors tried to account for the severity of portal hypertension by adjusting for liver stiffness, 16 the well-established impact of high HVPG values was neglected in their study, since the correlation with liver stiffness becomes weaker in patients with HVPG ≥10-12 mm Hg. 21, 37 Our findings are in line with Liu et al, 13 who also did not report an association between CAP values and the incidence of hepatic decompensation in a large cohort of patients at different stages of liver disease. However, the majority of patients included in the latter study did not have significant liver fibrosis. Thus, both malignancies other than HCC and cardiovascular events were more common than LRE. Unfortunately, the authors did not perform a subgroup analysis in patients with cACLD who are at considerable risk for developing hepatic decompensation in the short term. 13 Compensated and DC are two pathophysiologically distinct stages of liver disease. 26, 29, 38, 39 This is the first study to evaluate the prognostic impact of CAP in DC by investigating the determinants of further hepatic decompensation in a separate analysis. However, similar to patients with cACLD, CAP ≥248 dB/m was not predictive for further hepatic decompensation.
While we could not find any impact of CAP on hepatic decompensation, we were able to confirm the results of previous studies on predictors of first/further hepatic decompensation in patients with compensated and DC: Low serum albumin level and high MELD-Na were independently predictive for first hepatic decompensation in the setting of cACLD, which is in line with previous reports. 26, 40 Furthermore, MELD-Na and HPVG (in the subgroup of patients with available HVPG measurement) were independent predictors of further hepatic decompensation in patients with DC. 2 We have to acknowledge several limitations of our study. First, a considerable number of patients were excluded from analysis. As a consequence, sample size was limited. However, the absence of an association between CAP and hepatic decompensation cannot be explained by this limitation, since the rates of hepatic decompensation were even numerically (and statistically significantly) lower in cACLD patients with CAP ≥248 dB/m or CAP ≥220 dB/m.
Second, only a low number of patients with (N)AFLD aetiology were included; therefore, we cannot exclude that CAP has a prognostic impact on hepatic decompensation in these patients. Lastly, our study is limited by its retrospective single-centre design. However, clinical events were reviewed by two authors separately. Moreover, the incidence rates of first/further hepatic decompensation was in line with the literature, 17, 26, 41, 42 with ascites being the most common decompensation event. 39 In conclusion, CAP does not predict first/further hepatic decompensation in cACLD or in patients with DC. Serum albumin level and MELD-Na score are important independent predictors of first hepatic decompensation in cACLD, while MELD-Na and HVPG predicted further hepatic decompensation in patients with DC. 
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